source
- Vir hepatitis D drug succeeds in first pivotal studyA program that’s survived Vir’s pivot away from infectious disease research hit all of its study objectives and appeared more potent than a rival drug also in late-stage development.BioPharma Dive · 14h ago↗ source
- STAT+: Pharmalittle: We’re reading about a Novartis heart drug, BIO fighting a Trump program, and moreNovartis is largely abandoning a drug once considered a potential blockbuster after a study found it had little promise for preventing heart attacks and deathsSTAT · 16h ago↗ source
- Recon: FDA orders new eye risk warnings for Ozempic, Zepbound; FDA launches investigation of Novartis’ Zolgensma after cancer ca...Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.